PBM reform legislation has been moving through the US Congress for several years.
Most independent pharmacy owners have heard about it. Most have learned not to assume it will pass. Most have not thought carefully about what specifically changes if it does.
That last part is worth fixing.
Why this time is different
PBM reform has failed in Congress before.
The failure pattern has been consistent. Reform bills gain bipartisan support, pass committee with strong votes, attract broad advocacy coalition backing, and then stall before a floor vote as the legislative calendar fills with other priorities and PBM lobbying influence concentrates at the leadership level.
That pattern is real.
What is different in the current legislative environment is the convergence of several factors that have not previously aligned simultaneously.
State-level PBM reform has passed in more than thirty states over the past several years, establishing a legislative precedent and a body of state-level experience with reform mechanisms that makes federal action more politically navigable than it was previously.
The Federal Trade Commission released a report on PBM practices in 2024 that drew on years of investigation and presented specific findings about how PBM market concentration affects independent pharmacy and drug pricing in ways that have drawn attention from legislators who had not previously been deeply engaged on the issue.
Bipartisan consensus on PBM reform — rare in the current legislative environment for anything — has held more consistently on this topic than on most healthcare policy questions, because the pharmacy access argument resonates in rural districts represented by both parties.
None of this guarantees passage.
It does mean the probability distribution of outcomes is different from previous reform cycles.
What the leading reform proposals actually contain
The specific provisions in active reform legislation vary between bills, but the core elements that appear consistently across proposals are worth understanding.
PBM transparency requirements
The most consistent element across reform proposals is mandatory disclosure of PBM compensation, including spread pricing, administrative fees, and all other forms of revenue that PBMs generate from drug benefit programs.
Spread pricing — the practice of charging a plan sponsor more for a drug than the PBM reimburses the pharmacy — has been documented extensively in state Medicaid programs and has been the subject of significant regulatory and legislative action at the state level. Federal transparency requirements would extend this disclosure to commercial insurance markets and Medicare Part D.
For independent pharmacy owners, PBM transparency requirements have indirect value. They do not directly increase reimbursement. They create a documented record of PBM compensation practices that supports both regulatory action and future legislative reform.
Pharmacy reimbursement floors
Several active proposals include provisions establishing minimum reimbursement floors for pharmacy dispensing — requirements that PBMs reimburse pharmacies at or above a specified minimum relative to drug acquisition cost.
The implementation details vary significantly between proposals, and the specific minimum levels proposed range from meaningful to largely symbolic depending on how they are calculated.
If enacted, reimbursement floors would directly limit the most aggressive forms of below-cost reimbursement that have driven independent pharmacy closures in specific markets and drug categories.
Formulary and network access requirements
Several proposals include provisions requiring that any licensed pharmacy willing to meet the terms and conditions of a Part D plan network must be permitted to participate in that network.
If enacted, this provision would limit the preferred network structures through which PBMs have been able to concentrate dispensing volume at specific pharmacy chains while effectively excluding independents who cannot meet the volume and pricing requirements of preferred tier participation.
PBM ownership structure restrictions
The most structurally significant reform proposals address the vertical integration of PBMs with insurance companies, specialty pharmacies, and mail-order pharmacy operations.
The three largest PBMs are each owned by or affiliated with a major insurance company and each operate their own mail-order and specialty pharmacy operations. The argument that this integration creates conflicts of interest that harm independent pharmacy — and ultimately drug pricing and patient access — has gained significant traction in the current reform environment.
Structural remedies, including divestiture requirements or operational separation mandates, are the most consequential provisions under consideration and also the most uncertain in terms of passage.
What changes for your pharmacy if reform passes
The practical impact of PBM reform on your specific pharmacy depends on which provisions pass, how they are implemented, and how PBMs respond — because PBMs will respond.
The 2024 DIR fee reform is the most instructive precedent.
That reform eliminated a specific mechanism. PBMs restructured to preserve a comparable economic effect through different mechanisms.
The outcome for individual pharmacies varied from meaningful improvement to net neutrality depending on how their specific plan mix, network participation, and performance metrics interacted with the restructured contracts.
PBM reform legislation, if it passes, will follow the same pattern.
The specific mechanisms it addresses will change. The underlying incentive for PBMs to extract margin from the pharmacy channel will not change.
This is not an argument against reform. The transparency requirements, reimbursement floors, and network access provisions in current proposals would genuinely improve the operating environment for independent pharmacy relative to today.
It is an argument for continuing to audit your reimbursement position and build non-reimbursement revenue regardless of the legislative outcome.
Reform legislation is not a substitute for the financial discipline that determines whether your pharmacy survives the next three years. It is a potential improvement to the environment within which that discipline operates.
What state-level reform has already produced
While federal reform has moved slowly, state-level PBM reform has produced meaningful changes in multiple markets.
More than thirty states have passed some form of PBM regulation addressing spread pricing, network access, or transparency requirements. The results have been variable.
In states with strong spread pricing prohibition and effective enforcement, some independent pharmacy owners report meaningful improvement in Medicaid reimbursement adequacy. In states where reform language was weaker or enforcement mechanisms were underfunded, the practical impact has been limited.
The pattern mirrors what the 2024 federal DIR reform produced.
The legislative intent was clear. The implementation outcome varied significantly by pharmacy, by state, and by how PBMs restructured within the new rules.
The advocacy position that actually moves legislation
Most independent pharmacy owners who engage with PBM reform advocacy do so through their state or national pharmacy association.
That channel matters and deserves support.
It is also worth understanding what legislative advocacy is and is not.
Pharmacy associations are effective at providing technical expertise during the legislative drafting process, mobilizing constituent pharmacists to communicate with their representatives, and maintaining relationships with the legislative offices that work on healthcare policy.
They are less effective at the concentrated lobbying investment that PBMs and their affiliated insurance company owners bring to the same legislative process.
The advocacy resource asymmetry is real.
What moves the asymmetry is constituency visibility.
A legislator who hears from three independent pharmacy owners in their district — owners who can describe specifically what PBM practices have done to their pharmacy, their staff, and their patients — is more likely to prioritize floor vote scheduling than a legislator who has received only association advocacy materials.
The most effective advocacy action available to most independent owners is a direct constituent communication to their Congressional representative's office, describing their specific business situation in plain terms, not generic advocacy talking points.
That action takes thirty minutes. Its impact per dollar of investment is higher than most other advocacy activities available to independent pharmacy owners.
What to watch in the next twelve months
The legislative provisions most likely to move first are those with the clearest bipartisan support and the lowest complexity of implementation.
PBM transparency and disclosure requirements meet both criteria. Watch for these in any healthcare legislation moving through Congress as a potential vehicle for attachment.
Reimbursement floor provisions have strong independent pharmacy advocacy support but face more significant PBM lobbying opposition. These are less likely to move independently and more likely to appear as part of a larger negotiated package.
Structural integration remedies face the most significant opposition and the longest timeline. These are worth tracking as a long-term directional question rather than a near-term operational planning input.
Regardless of what passes federally, continue watching state-level PBM legislation in your state. State-level reform has moved faster than federal reform and has produced some of the most meaningful changes in independent pharmacy reimbursement in specific markets over the past several years.
The bottom line
PBM reform legislation matters for independent pharmacy.
The current reform environment is more serious than previous cycles.
And the outcome of that reform, whatever it is, will not replace the work of understanding your specific reimbursement position, auditing your contracts, and building revenue that does not depend on PBM decisions.
Reform improves the environment. Financial discipline determines your outcomes within it.
Both matter. Neither substitutes for the other.
Read next on Blinkerhub:
The reimbursement audit that gives you the clearest picture of your current position — regardless of what legislation passes — is the most useful preparation for whatever the reform environment produces.
The non-PBM revenue streams that change your business's risk profile regardless of the legislative outcome are covered in the compounding physician relationship strategy and the MTM billing guide.
Blinkerhub is a free weekly intelligence newsletter for independent pharmacy owners worldwide. Not affiliated with any PBM, chain pharmacy, trade association, or pharmacy software vendor. Published every Tuesday at pharmacy.blinkerhub.com.
Legislative details and reform provisions change as bills are amended and move through the legislative process. Verify current bill status and provisions with your state and national pharmacy association.